Granted Patent
B2
US 9,593,164 · App. 14/086,588 · Granted Mar 14, 2017
Bispecific EGFR/c-Met antibodies
Inventors:
Mark Chiu (Spring House, PA); Sheri Moores (Spring House, PA); Joost Neijssen (Ultrecht, NL); Paul Parren (Ultrecht, NL); Janine Schuurman (Ultrecht, NL)
Assignee:
Janssen Biotech, Inc.
C07K16/2863A61K31/437A61K31/4545A61K31/517A61K31/5377A61K33/24A61K39/395A61K39/3955A61K45/06A61K2039/505C07K2317/31C07K2317/73C07K2317/76C07K2318/20
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
Claims (6)
1. An isolated bispecific epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody, comprising:
a) a first heavy chain (HC1);
b) a second heavy chain (HC2);
c) a first light chain (LC1); and
d) a second light chain (LC2) wherein the HC1, the LC1, the HC2 and the LC2 comprise amino acid sequences of SEQ ID NOs: 199, 200, 201 and 202, respectively.
2. A pharmaceutical composition comprising the bispecific antibody of claim 1 and a pharmaceutically acceptable carrier.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 20, 2014
From: CHIU, MARK; MOORES, SHERI; NEIJSSEN, JOOST; PARREN, PAUL; SCHUURMAN, JANINE
To: JANSSEN BIOTECH, INC.
Reel/Frame 032929/0113 →
Continuity (6)
Provisional Application
61728912
· Nov 21, 2012
Provisional Application
61782550
· Mar 14, 2013
Provisional Application
61809541
· Apr 8, 2013
Provisional Application
61864717
· Aug 12, 2013
Provisional Application
61892797
· Oct 18, 2013